论文部分内容阅读
mdm2基因与p53基因间存在相互调节网络,可望成为基因治疗的靶基因,本文应用反转录PCR反应、PCR联合限制性内切酶反应方法,研究了42例癌组织和25例癌周肝组织中mdm2基因表达与p53基因第七外显子第249密码子突变的相互关系.结果提示mdm2基因表达值(均数±标准误)在p53基因未突变肝癌组(62.1%±8.4%)高于p53基因突变肝癌组(38.5±4.8%,P<0.5),也高于癌周肝组织(p53基因无突变)(26.2%±5.1%,P<0.01),而在p53基因突变组(38.5±4.8%)与癌周肝(26.2%±5.1%,P>0.05)间无明显差别.病灶多发肝癌与病灶单发肝癌相比,mdm2基因表达值(均数±标准误)在病灶多发组(68.9%±10.1%)明显高于病灶单发组(42.6±4.2%,<0.05),而p53基因第249密码子突变率则明显差别(40%对44%,P<0.05).
The mdm2 gene and p53 gene have mutual regulatory networks and are expected to become target genes for gene therapy. In this paper, 42 cases of cancer tissues and 25 cases of hepatic cancer were studied by using reverse transcription PCR reaction and PCR combined with restriction endonuclease reaction method. The correlation between mdm2 gene expression in the tissues and the 249 codon mutation in exon 7 of p53 gene. The results suggest that the mdm2 gene expression value (mean ± standard error) is higher in the p53 gene-unmutated liver cancer group (62.1% ± 8.4%). The p53 gene mutation in the HCC group (38.5±4.8%, P<0.5) was also higher than that in the cancer tissue (p53 gene without mutation) (26.2%±5.1%, P<0.01), while in the p53 gene mutation group (38.5). There was no significant difference between ±4.8%) and cancerous liver (26.2%±5.1%, P>0.05). The mdm2 gene expression value (mean±standard error) was more common in lesions with multiple hepatocellular carcinoma and single hepatocellular carcinoma. (68.9%±10.1%) was significantly higher than the single lesion group (42.6±4.2%,<0.05), while the mutation rate of the 249 codon of the p53 gene was significantly different (40% vs. 44%, P<0.05).